RBOT: AI 评分 46/100 — AI 分析 (4月 2026)

Vicarious Surgical Inc. is pioneering minimally invasive surgery through its single-incision surgical robot, the Vicarious System, initially targeting ventral hernia repair. The company aims to revolutionize surgical procedures by virtually transporting surgeons inside the patient.

Key Facts: Price: $2.66 AI Score: 46/100 Sector: Healthcare

公司概况

概要：

Vicarious Surgical is transforming minimally invasive surgery with its innovative single-incision surgical robot, offering enhanced precision and reduced patient trauma. Targeting a multi-billion dollar market, RBOT presents a compelling opportunity for investors seeking disruptive healthcare technologies and long-term growth potential in the medical device sector.

RBOT是做什么的？

Vicarious Surgical Inc., founded in 2014 and headquartered in Waltham, Massachusetts, is at the forefront of surgical robotics, developing and commercializing the Vicarious System, a single-incision surgical robot designed to enhance minimally invasive surgery. The company's core mission is to virtually transport surgeons inside the patient, providing unparalleled precision and dexterity through its proprietary technology. Initially focused on ventral hernia repair, the Vicarious System aims to improve surgical outcomes, reduce patient recovery times, and lower overall healthcare costs. Vicarious Surgical's evolution is rooted in addressing the limitations of traditional laparoscopic and robotic surgical techniques. The Vicarious System stands out due to its ability to enter the body through a single incision, offering a less invasive approach compared to multi-port robotic systems. This innovative design allows for greater maneuverability and visualization within the surgical field. The company's commitment to innovation is reflected in its ongoing research and development efforts to expand the applications of the Vicarious System to other surgical procedures. Vicarious Surgical's market position is characterized by its focus on a specific niche within the broader surgical robotics market, emphasizing single-incision surgery. While the company is still in the early stages of commercialization, its technology holds significant promise for disrupting the surgical landscape and improving patient care. As of 2026, Vicarious Surgical continues to refine its technology and build strategic partnerships to drive adoption of the Vicarious System in hospitals and surgical centers.

RBOT的投资论点是什么？

Vicarious Surgical presents a notable market position due to its innovative single-incision surgical robot, the Vicarious System, which addresses a significant need for less invasive surgical options. The company's initial focus on ventral hernia repair represents a substantial market opportunity, with potential for expansion into other surgical specialties. Key value drivers include successful commercialization of the Vicarious System, expansion of its clinical applications, and strategic partnerships with hospitals and surgical centers. With a market capitalization of $0.01 billion and a Beta of 1.55, RBOT offers high-growth potential, albeit with inherent risks associated with early-stage medical device companies. The absence of a dividend reflects the company's focus on reinvesting earnings to fuel growth. Successful execution of its commercialization strategy and achievement of regulatory milestones are critical catalysts for driving shareholder value. RBOT may be worth researching as a long-term investment, recognizing the potential for significant returns as the company gains market share and establishes its technology as a standard of care in minimally invasive surgery.

RBOT在哪个行业运营？

Vicarious Surgical operates within the dynamic and rapidly evolving medical device industry, specifically in the surgical robotics segment. The market for surgical robots is experiencing substantial growth, driven by increasing demand for minimally invasive procedures, technological advancements, and an aging population. Competitors include companies like BOLD, HYPD, INTS, ITRM, and MODD, each offering different approaches to surgical robotics. Vicarious Surgical differentiates itself through its focus on single-incision surgery, offering a potentially less invasive alternative to traditional multi-port robotic systems. The company's success depends on its ability to navigate regulatory hurdles, secure market adoption, and maintain a competitive edge in a rapidly changing landscape.

Medical - Devices

Healthcare

RBOT有哪些增长机遇？

Expansion into New Surgical Specialties: Vicarious Surgical has a significant opportunity to expand the applications of its Vicarious System beyond ventral hernia repair. By targeting other surgical specialties, such as colorectal surgery, bariatric surgery, and gynecological procedures, the company can significantly increase its addressable market. Each of these specialties represents a multi-billion dollar market, offering substantial growth potential. This expansion will require further clinical trials and regulatory approvals, with a timeline of 3-5 years.
Strategic Partnerships with Hospitals and Surgical Centers: Forming strategic partnerships with leading hospitals and surgical centers is crucial for driving adoption of the Vicarious System. These partnerships can provide access to key opinion leaders, facilitate clinical trials, and establish the Vicarious System as a standard of care. By collaborating with established healthcare providers, Vicarious Surgical can accelerate its commercialization efforts and gain a competitive advantage. These partnerships can be forged within the next 1-2 years.
Development of AI-Powered Surgical Assistance: Integrating artificial intelligence (AI) into the Vicarious System can enhance surgical precision, improve workflow efficiency, and reduce surgeon fatigue. AI-powered surgical assistance can provide real-time guidance, automate repetitive tasks, and analyze surgical data to optimize outcomes. This technological advancement can further differentiate the Vicarious System and attract a wider range of surgeons. Development and integration could take 2-4 years.
Geographic Expansion into International Markets: Expanding into international markets, such as Europe and Asia, represents a significant growth opportunity for Vicarious Surgical. These markets offer large patient populations and increasing demand for minimally invasive surgery. However, international expansion requires navigating complex regulatory landscapes and adapting the Vicarious System to meet local market needs. This expansion could begin within 3-5 years.
Securing Reimbursement Coverage from Payers: Obtaining favorable reimbursement coverage from public and private payers is essential for driving adoption of the Vicarious System. Without adequate reimbursement, hospitals and surgical centers may be reluctant to invest in the technology. Vicarious Surgical needs to demonstrate the clinical and economic benefits of the Vicarious System to secure favorable reimbursement rates. Ongoing efforts are required to demonstrate value and secure coverage.

Vicarious Surgical is focused on developing a single-incision surgical robot, offering a less invasive approach compared to traditional multi-port robotic systems.
The Vicarious System is initially targeting ventral hernia repair, a significant market with potential for expansion into other surgical specialties.
The company's innovative technology aims to improve surgical outcomes, reduce patient recovery times, and lower overall healthcare costs.
Vicarious Surgical's market capitalization is $0.01 billion, reflecting its early-stage growth potential.
The company's Beta of 1.55 indicates higher volatility compared to the overall market, typical for growth-oriented companies in the medical device sector.

RBOT提供哪些产品和服务？

Develops and sells the Vicarious System, a single-incision surgical robot.
Offers a minimally invasive surgical solution designed to virtually transport surgeons inside the patient.
Focuses on ventral hernia repair as its initial target market.
Aims to improve surgical outcomes and reduce patient recovery times.
Provides surgeons with enhanced precision and dexterity during surgical procedures.
Continues to research and develop new applications for the Vicarious System.

RBOT如何赚钱？

Sells the Vicarious System surgical robot to hospitals and surgical centers.
Generates revenue through service and maintenance contracts for the Vicarious System.
Plans to generate revenue through disposable instruments and accessories used with the Vicarious System.
Potentially generates revenue through training programs for surgeons using the Vicarious System.

Hospitals seeking to offer advanced minimally invasive surgical options.
Surgical centers specializing in hernia repair and other minimally invasive procedures.
Surgeons looking for enhanced precision and control during surgery.
Patients seeking less invasive surgical options with faster recovery times.

Proprietary single-incision surgical robot technology.
Strong intellectual property portfolio protecting its innovations.
First-mover advantage in the single-incision surgical robotics market.
Potential for network effects as more surgeons adopt the Vicarious System.

什么因素可能推动RBOT股价上涨？

Upcoming: Successful completion of clinical trials for new surgical applications.
Upcoming: Regulatory approvals for expanded indications of the Vicarious System.
Ongoing: Strategic partnerships with leading hospitals and surgical centers.
Ongoing: Positive clinical data demonstrating the benefits of the Vicarious System.
Ongoing: Increasing market awareness and adoption of the Vicarious System.

RBOT的主要风险是什么？

Potential: Competition from established players in the surgical robotics market.
Potential: Regulatory hurdles and delays.
Potential: Technological obsolescence.
Ongoing: Economic downturn affecting hospital capital spending.
Ongoing: Dependence on key personnel and suppliers.

RBOT的核心优势是什么？

Innovative single-incision surgical robot technology.
Potential to improve surgical outcomes and reduce patient recovery times.
Strong intellectual property portfolio.
Experienced management team.

RBOT的劣势是什么？

Early-stage company with limited commercialization experience.
High development and regulatory costs.
Limited market awareness.
Reliance on key personnel.

RBOT有哪些机遇？

Expansion into new surgical specialties.
Strategic partnerships with hospitals and surgical centers.
Development of AI-powered surgical assistance.
Geographic expansion into international markets.

RBOT面临哪些威胁？

Competition from established players in the surgical robotics market.
Regulatory hurdles and delays.
Technological obsolescence.
Economic downturn affecting hospital capital spending.

RBOT的竞争对手是谁？

Bolder Surgical — Focuses on laparoscopic instruments and devices. — (BOLD)
Hyperfine Inc. — Develops portable MRI systems. — (HYPD)
Intuitive Surgical Inc. — A leader in robotic surgery with the da Vinci Surgical System. — (INTS)
Iterum Therapeutics PLC — Focuses on developing anti-infectives. — (ITRM)
Modular Medical Inc. — Develops insulin delivery systems. — (MODD)

Key Metrics

Price: $2.66 (+5.56%)
Market Cap: $17.2M
Volume: 322,798
MoonshotScore: 46/100

Company Profile

CEO: Stephen From
Headquarters: Waltham, MA, US
Employees: 123
Founded: 2020

AI Insight

Vicarious Surgical Inc. is a medical device company focused on developing and selling a single-incision surgical robot. Their Vicarious System is designed for minimally invasive surgery, initially targeting ventral hernia repair.

常见问题

What does Vicarious Surgical Inc. do?

Vicarious Surgical Inc. is a medical device company focused on revolutionizing minimally invasive surgery through its innovative Vicarious System. This single-incision surgical robot is designed to virtually transport surgeons inside the patient, offering enhanced precision and dexterity. The company's initial focus is on ventral hernia repair, but it aims to expand the applications of the Vicarious System to other surgical specialties. By improving surgical outcomes, reducing patient recovery times, and lowering overall healthcare costs, Vicarious Surgical seeks to transform the surgical landscape and establish its technology as a standard of care.

Is RBOT stock a good buy?

RBOT stock presents a high-risk, high-reward investment opportunity. While the company's innovative technology and potential for growth are compelling, investors should carefully consider the risks associated with early-stage medical device companies. Key metrics to watch include progress on regulatory approvals, commercialization efforts, and expansion into new surgical specialties. A balanced analysis requires considering both the potential for significant returns and the inherent uncertainties in the medical device industry. Investors should conduct thorough due diligence and assess their risk tolerance before investing in RBOT.

What are the main risks for RBOT?

The main risks for RBOT include competition from established players in the surgical robotics market, regulatory hurdles and delays, technological obsolescence, and economic downturn affecting hospital capital spending. Competition from companies like Intuitive Surgical (INTS) poses a significant challenge. Regulatory approvals are crucial for expanding the applications of the Vicarious System, and delays could impact the company's growth trajectory. Rapid technological advancements in the surgical robotics field could render the Vicarious System obsolete if the company fails to innovate continuously. Economic downturns could reduce hospital capital spending, affecting demand for the Vicarious System.